E10030
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for E10030, covering 2020-07-14 to 2020-07-14. Get the full timeline:
Most recent: Clinical Trial Update: A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab [Phase 1, Phase 2]